In this manuscript, we reported the generation of EGFR- and HER2-targeting T-BsAbs, as well as a heterodimeric EGFRxHER2 T-BsAb, capable of driving T cell infiltration and eliciting impressive in vivo anti-tumor potency against established cell-derived and patient-derived PDAC xenografts. This evidence concerns the gene ERBB2 and neoplasm.